Seller record · Telehealth service
Evernow
Fails 3 of 8 criteria. S3, pharmacy identification: No filling pharmacy is named. Prescriptions go to the patient's local pharmacy or are delivered home, and the terms say the company endorses no specific pharmacy. 2 more criteria also fail; see the table below.
At a glance
EvernowTelehealth service
- Price
- Not printed before a consultation or sign-up
- Sells
- Wegovy, Ozempic, Rybelsus, and 4 more
- FDA letters
- None on file
Telehealth service. Passes 5 of 8 criteria. Recorded against Standard v1.1.
A San Francisco telehealth service for women in perimenopause and menopause whose affiliated medical groups prescribe brand-name GLP-1 medications such as Wegovy, Zepbound, Ozempic and Mounjaro, alongside hormone therapy, through a monthly membership or paid video visits.
Operating entity Evernow, Inc.
Dispositions
| Code | Criterion | Disposition | Where it appears |
|---|---|---|---|
| S1 | Prescriber requirement | PASS | Evernow's terms; Evernow's weight loss page |
| S2 | Prescription gating | PASS | Evernow's weight loss page; Evernow's how it works page |
| S3 | Pharmacy identification | FAIL | Evernow's weight loss page; Evernow's terms |
| S4 | Compounding disclosure | PASS | Evernow's weight loss page |
| S5 | Analytical documentation | FAIL | Evernow's weight loss page; Evernow's FAQ; Evernow's terms |
| S6 | Business address | PASS | Evernow's privacy page |
| S7 | Price disclosure | FAIL | Evernow's FAQ; Evernow's how it works page; Evernow's weight loss page |
| S8 | Enforcement status | PASS | FDA warning-letter index |
Evidence, criterion by criterion
The evidence behind each disposition in the table above, where it appears, and its date.
Products shown on the seller's own pages at the recorded date: Wegovy, Ozempic, Rybelsus, Mounjaro, Zepbound, Contrave, hormone therapy.
Other sellers of the same products
Dispositions recorded against Standard v1.1. Method and null semantics: how checks are performed. This record is not a review and contains no medical advice.